Atmosphere-ph.ru

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru

ИНТЕРНЕТ-МАГАЗИН

Лечебное дело
2021 / N 3

Лекарственно-индуцированные заболевания легких
О.Д. Остроумова, А.И. Листратов, А.И. Кочетков, Д.А. Сычев

Список литературы

1. Macdonald G. Harrison’s internal medicine, 17th edition. Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, Loscalzo J, editors. Internal Medicine Journal 2008 Dec;38(12):932.
2. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine 2013 Sep;188(6):733-48.
3. Коды МКБ-10: J80-J84 – другие респираторные болезни, поражающие главным образом интерстициальную ткань. Доступно по: https://mkb10.su/J80-J84.html Ссылка активна на 23.10.2021.
4. Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018: 431-49.
5. Коды МКБ-10: J70 – респираторные состояния, вызванные другими внешними агентами. Доступно по: https://mkb10.su/J70.html Ссылка активна на 23.10.2021.
6. Schwaiblmair M, Behr W, Haeckel T, Märkl B, Foerg W, Berghaus T. Drug-induced interstitial lung disease. The Open Respiratory Medicine Journal 2012;6:63-74.
7. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. American Journal of Respiratory and Critical Care Medicine 1994 Oct;150(4):967-72.
8. Amar RK, Jick SS, Rosenberg D, Maher TM, Meier CR. Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosis. Respirology (Carlton, Vic.) 2012 Jul;17(5):861-8.
9. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of Internal Medicine 2012 May;156(10):684-91.
10. Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. British Journal of Cancer 1998 Oct;78(8):1061-6.
11. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. The European Respiratory Journal 2000 Feb;15(2):373-81.
12. Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone: review of pulmonary effects and toxicity. Drug Safety 2010 Jul;33(7):539-58.
13. Chen YM, Luo YH. Interstitial lung disease induced by targeted therapy for non-small cell lung cancer: a review of diagnosis, workup, and management. Journal of Palliative Care & Medicine 2015;5:204.
14. Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, Giollo A, Wild JM, Waterton JC, Buch M, Linton K, Bruce IN, Leonard C, Bianchi S, Chaudhuri N. Drug-induced interstitial lung disease: a systematic review. Journal of Clinical Medicine 2018 Oct;7(10):356.
15. Collard HR, Ward AJ, Lanes S, Hayflinger DC, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. Journal of Medical Economics 2012;15(5):829-35.
16. Dweik RA. Drug-induced pulmonary disease. In: Textbook of pulmonary diseases. Baum GL, Crapo JD, Celli BR, Karlinsky JB, editors. 2-vol. set. 6th ed. Philadelphia, PA: Lippincott-Raven; 1988: 477-90.
17. Ahmed BM, Al-Zakwani IS. Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman. Journal of Oncology Pharmacy Practice 2013 Mar;19(1):3-7.
18. Tamura M, Saraya T, Fujiwara M, Hiraoka S, Yokoyama T, Yano K, Ishii H, Furuse J, Goya T, Takizawa H, Goto H. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. The Oncologist 2013;18(4):454-9.
19. Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer (Amsterdam, Netherlands) 2014 Feb;83(2):231-9.
20. Osawa M, Kudoh S, Sakai F, Endo M, Hamaguchi T, Ogino Y, Yoneoka M, Sakaguchi M, Nishimoto H, Gemma A. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Journal of Clinical Oncology 2015 Dec;20(6):1063-71.
21. Ishiguro M, Watanabe T, Yamaguchi K, Satoh T, Ito H, Seriu T, Sakata Y, Sugihara K. A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer. Japan Journal of Clinical Oncology 2012 Apr;42(4):287-94.
22. Ou SHI. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Expert Review of Anticancer Therapy 2012 Feb;12(2):151-62.
23. Wu S, Liu K, Ren F, Zheng D, Pan D. Fatal interstitial lung disease associated with crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report. BMC Pulmonary Medicine 2018 Jul;18(1):121.
24. Cooper MR, Chim H, Chan H, Durand C. Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. The Annals of Pharmacotherapy 2015 Jan;49(1):107-12.
25. Bender L, Meyer G, Quoix E, Mennecier B. Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report. Annals of Translational Medicine 2019 Mar;7(5):106.
26. Alkhunaizi AM, Al-Khouzaie TH, Alsagheir AI. Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus. Respiratory Medicine Case Reports 2020 Jun;30:101109.
27. Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 2017 Aug;152(2):271-81.
28. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncology 2016 Dec;2(12):1607-16.
29. Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, Zamami Y, Nishioka Y, Ishizawa K. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Scientific Reports 2020 Aug;10(1):13773.
30. Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 2013 Mar;143(3):858-61.
31. Yoshii N, Suzuki T, Nagashima M, Kon A, Kakihata K, Gemma A. Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports. Anti-cancer Drugs 2011 Jul;22(6):563-8.
32. Otoshi R, Sekine A, Hagiwara E, Okudela K, Katano T, Aiko N, Matama G, Isomoto K, Ikeda S, Baba T, Komatsu S, Ogura T. Pemetrexed-induced interstitial lung disease mimicking hypersensitivity pneumonia: a pathologically proven case. Internal Medicine (Tokio, Japan) 2019 Sep;58(18):2679-82.
33. Iki S, Yoshinaga K, Ohbayashi Y, Urabe A. Cytotoxic drug-induced pneumonia and possible augmentation by G-CSF – clinical attention. Annals of Hematology 1993 Apr;66(4):217-8.
34. Yamasaki K, Yatera K, Noguchi S, Oda K, Akata K, Nishida C, Kawanami T, Kawanami Y, Ishimoto H, Ono S, Wakuta Y, Mukae H. Incidence and outcomes of bepridil-induced interstitial pneumonia. Respiratory Medicine 2013 Dec;107(12):2088-91.
35. Pervaiz S, Homsy S, Narula N, Ngu S, Elsayegh D. Bevacizumab-induced pneumonitis in a patient with metastatic colon cancer: a case report. Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine 2020 Jun;14:1179548420929285.
36. Yamaguchi T, Seki T, Miyasaka C, Inokuchi R, Kawamura R, Sakaguchi Y, Murata M, Matsuzaki K, Nakano Y, Uemura Y, Okazaki K. Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: an autopsy case report. Oncology Letters 2015 Apr;9(4):1633-6.
37. Naqibullah M, Shaker SB, Bach KS, Bendstrup E. Rituximab-induced interstitial lung disease: five case reports. European Clinical Respiratory Journal 2015 May 21;2. doi: 10.3402/ecrj.v2.27178. eCollection 2015.
38. Nishino M, Boswell EN, Hatabu H, Ghobrial IM, Ramaiya NH. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenström macroglobulinemia as a paradigm. Oncologist 2015 Sep;20(9):1077-83.
39. Kharel P, Uprety D, Chandra AB, Hu Y, Belur AA, Dhakal A. Bortezomib-induced pulmonary toxicity: a case report and review of literature. Case Reports in Medicine 2018 Nov;2018:2913124.
40. Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P, Malcovati L, Nascimbene C, Varettoni M, Volpini E, Klersy C, Bernasconi C. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplantation 2000 Feb;25(3):309-13.
41. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis & Rheumatology (Hoboken, N.J.) 2014 Apr;66(4):803-12.
42. Drosos AA, Psychos D, Andonopoulos AP, Stefanaki-Nikou S, Tsianos EB, Moutsopoulos HM. Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up. Clinical Rheumatology 1990 Sep;9(3):333-41.
43. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ 2015 Mar;350:h1269.
44. Sen S, Peltz C, Jordan K, Boes TJ. Infliximab-induced nonspecific interstitial pneumonia. The American Journal of the Medical Sciences 2012 Jul;344(1):75-8.
45. Manfredi A, Cassone G, Furini F, Gremese E, Venerito V, Atzeni F, Arrigoni E, Della Casa G, Cerri S, Govoni M, Petricca L, Iannone F, Salvarani C, Sebastiani M. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Internal Medicine Journal 2020 Sep;50(9):1085-90.
46. Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, Joh T, Ohtsu A. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Annals of Oncology 2010 Oct;21(10):2005-10.
47. Yoneda KY, Cross CE. The pulmonary toxicity of anticancer agents. In: Respiratory Toxicology. Vol. 8. Elsevier; 2010: 477-510.
48. Matijasic N, Bonevski A, Pivac VT, Pavic I. Busulfan-induced lung injury in pediatric oncology patients-review of the literature with an illustrative case. Pediatric Allergy, Immunology, and Pulmonology 2019 Sep;32(3):86-91.
49. Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, Matsuda T, Takemura T, Sagawa A; Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford, England) 2009 Sep;48(9):1069-72.
50. Smith W, Ball GV. Lung injury due to gold treatment. Arthritis & Rheumatology 1980 Mar;23(3):351-4.
51. Fernández AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008 Oct;134(4):824-30.
52. Santos JM, Batech M, Pelter MA, Deamer RL. Evaluation of the risk of nitrofurantoin lung injury and its efficacy in diminished kidney function in older adults in a large integrated healthcare system: a matched cohort study. Journal of the American Geriatrics Society 2016 Apr;64(4):798-805.
53. Higashi Y, Nakamura S, Tsuji Y, Ogami C, Matsumoto K, Kawago K, Tokui K, Hayashi R, Sakamaki I, Yamamoto Y. Daptomycin-induced eosinophilic pneumonia and a review of the published literature. Internal Medicine (Tokio, Japan) 2018 Jan;57(2):253-8.
54. Mankikian J, Favelle O, Guillon A, Guilleminault L, Cormier B, Jonville-Béra AP, Perrotin D, Diot P, Marchand-Adam S. Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. Respiratory Medicine 2014 Apr;108(4):638-46.
55. Vanina B, Delay M, Vigreux P, Montastruc JL, Lapeyre-Mestre M. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. American Journal of Therapeutics 2006 Jul-Aug;13(4):315-9.
56. Tisdale JE, Follin SL, Ordelova A, Webb CR. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. Journal of Clinical Pharmacology 1995 Apr;35(4):351-6.
57. Pollak PT, Sharma AD, Carruthers SG. Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. The American Journal of Cardiology 1990 May;65(18):1185-91.
58. Hanston P, Evrard P, Mahieu P, Wallemacq P, Friob M, Hassoun A. Flecainide-associated interstitial pneumonitis. The Lancet 1991 Feb;337(8737):371-2.
59. Pesenti S, Lauque D, Daste G, Boulay V, Pujazon MC, Carles P. Diffuse infiltrative lung disease associated with flecainide. Report of two cases. Respiration 2002;69(2):182-5.
60. Akoun GM, Cadranel JL, Israel-Biet D, Gauthier-Rahman S. Flecainide-associated pneumonitis. The Lancet 1991 Jan;337(8732):49.
61. Deidda A, Pisanu C, Micheletto L, Bocchetta A, Del Zompo M, Stochino ME. Interstitial lung disease induced by fluoxetine: systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database. Pharmacological Research 2017 Jun;120:294-301.
62. Turner RC, Nelson JE, Roberts BT, Gillam DM. Venlafaxine-associated interstitial pneumonitis. Pharmacotherapy 2005 Apr;25(4):626-9.
63. Thornton C, Maher TM, Hansell D, Nicholson AG, Wells AU. Pulmonary fibrosis associated with psychotropic drug therapy: a case report. Journal of Medical Case Reports 2009 Nov;3:126.
64. Espeleta VJ, Moore WH, Kane PB, Baram D. Eosinophilic pneumonia due to duloxetine. Chest 2007 Mar;131(3):901-3.
65. Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleveland Clinic Journal of Medicine 2001 Sep;68(9):782-5, 789-95.
66. Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Digestive Diseases and Sciences 2010 Mar;55(3):579-85.
67. Camus P. The Drug-Induced Respiratory Disease Website. Available from: https://www.pneumotox.com/drug/index/ Accessed 2021 Oct 23.
68. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Seminars in Arthritis and Rheumatism 2014 Apr;43(5):613-26.
69. O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Annals of Oncology 2003 Jan;14(1):91-6.
70. Schmitz N, Diehl V. Carmustine and the lungs. The Lancet 1997 Jun;349(9067):1712-3.
71. Min JH, Lee HY, Lim H, Ahn MJ, Park K, Chung MP, Lee KS. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemotherapy and Pharmacology 2011 Nov;68(5):1099-109.
72. Roelandt M, Demedts M, Callebaut W, Coolen D, Slabbynck H, Bockaert J, Kips J, Brie J, Ulburghs M, De Boeck K. Epidemiology of interstitial lung disease (ILD) in flanders: registration by pneumologists in 1992–1994. Working group on ILD, VRGT. Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding. Acta Clinica Belgica 1995;50(5):260-8.
73. Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology 1994 Jul;107(1):266-70.
74. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Canadian Respiratory Journal 2009 Mar-Apr;16(2):43-8.
75. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respiratory Research 2012;13(1):39.
76. Ryrfeldt A. Drug-induced inflammatory responses to the lung. Toxicology Letters 2000 Mar;112-3:171-6.
77. Mendez JL, Nadrous HF, Hartman TE, Ryu JH. Chronic nitrofurantoin-induced lung disease. Mayo Clinic Proceedings 2005 Oct;80(10):1298-302.
78. Kim YJ, Song M, Ryu JC. Mechanisms underlying methotrexate-induced pulmonary toxicity. Expert Opinion on Drug Safety 2009 Jul;8(4):451-8.
79. Lee WI, Hissaria P. Drug-induced interstitial lung disease. Indian Journal of Rheumatology 2019;14(5):19-26.
80. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer (Amsterdam, Netherlands) 2004 Jul;45(1):93-104.
81. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Research 2003 Aug;63(16):5054-9.
82. Baritussio A, Marzini S, Agostini M, Alberti A, Cimenti C, Bruttomesso D, Manzato E, Quaglino D, Pettenazzo A. Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes. American Journal of Physiology. Lung Cellular and Molecular Physiology 2001 Nov;281(5):L1189-99.
83. Cooper JA Jr, Zitnik RJ, Matthay RA. Mechanisms of drug-induced pulmonary disease. Annual Review of Medicine 1988;39:395-404.
84. Coombs PRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Clinical aspects of immunology. Gell PRA, editor. Oxford: Oxford University Press; 1968: 575-96.
85. Schnyder B, Pichler WJ. Mechanisms of drug-induced allergy. Mayo Clinic Proceedings 2009 Mar;84(3):268-72.
86. Gruchalla RS. Drug metabolism, danger signals, and drug-induced hypersensitivity. The Journal of Allergy and Clinical Immunology 2001 Oct;108(4):475-88.
87. Matzinger P. The danger model: a renewed sense of self. Science 2002 Apr;296(5566):301-5.
88. Partanen J, van Assendelft AH, Koskimies S, Forsberg S, Hakala M, Ilonen J. Patients with rheumatoid arthritis and gold-induced pneumonitis express two high-risk major histocompatibility complex patterns. Chest 1987 Aug;92(2):277-81.
89. Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms AM, van de Putte LB. Methotrexate-related pulmonary complications in rheumatoid arthritis. Annals of the Rheumatic Diseases 1994 Jul;53(7):434-9.
90. White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. American Journal of Respiratory and Critical Care Medicine 2010 Aug;182(3):396-403.
91. Camus P, Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Clinics in Chest Medicine 2004 Mar;25(1):65-75.
92. Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clinics in Chest Medicine 1990 Mar;11(1):1-20.
93. Aronin PA, Mahaley MS Jr, Rudnick SA, Dudka L, Donohue JF, Selker RG, Moore P. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. The New England Journal of Medicine 1980 Jul;303(4):183-8.
94. Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 1997 Mar;111(3):657-60.
95. O’Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. The New England Journal of Medicine 1990 Aug;323(6):378-82.
96. Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, St Clair EW, Sundy JS, Alexander RW, Smith GJ, Axiotis CA. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Annals of Internal Medicine 1997 Sep;127(5):356-64.
97. Tomii K, Kato T, Takahashi M, Noma S, Kobashi Y, Enatsu S, Okubo S, Kobayashi N, Kudoh S. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer). Japanese Journal of Clinical Oncology 2017 Apr;47(4):350-6.
98. Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Minakuchi K, Ishizawa K. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. The Annals of Pharmacotherapy 2015 Apr;49(4):398-404.
99. Camus P, Bonniaud P, Fanton A, Camus C, Baudaun N, Foucher P. Drug-induced and iatrogenic infiltrative lung disease. Clinics in Chest Medicine 2004 Sep;25(3):479-519, vi.
100. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, Narimatsu H, Fujii T, Kawabata M, Taniguchi S, Ozawa K, Oshimi K. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006 May;107(9):3492-4.
101. Ohri A, Arena FP. Severe pulmonary complications in African-American patient after bortezomib therapy. American Journal of Therapeutics 2006 Nov-Dec;13(6):553-5.
102. Iqbal K, Kelly C. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Therapeutic Advances in Musculoskeletal Disease 2015 Dec;7(6):247-67.
103. Wijnen PA, Drent M, Nelemans PJ, Kuijpers PM, Koek GH, Neef C, Haenen GR, Bekers O. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands. Drug Safety 2008;31(12):1125-34.
104. Hamada T, Yasunaga H, Nakai Y, Isayama H, Matsui H, Fushimi K, Koike K. Interstitial lung disease associated with gemcitabine: a Japanese retrospective cohort study. Respirology (Carlton, Vic.) 2016 Feb;21(2):338-43.
105. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004 Jul-Aug;71(4):301-26.
106. Sahin IH, Geyer AI, Kelly DW, O’Reilly EM. Gemcitabine-related pneumonitis in pancreas adenocarcinoma – an infrequent event: elucidation of risk factors and management implications. Clinical Colorectal Cancer 2016 Mar;15(1):24-31.
107. Weiner SM, Sellin L, Vonend O, Schenker P, Buchner NJ, Flecken M, Viebahn R, Rump LC. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome – a single-centre experience and review of the literature. Nephrology, Dialysis, Transplantation 2007 Dec;22(12):3631-7.
108. Daba MH, El-Tahir KE, Al-Arifi MN, Gubara OA. Drug-induced pulmonary fibrosis. Saudi Medical Journal 2004 Jun;25(6):700-6.
109. Lessnau KD. Drug-induced pulmonary toxicity clinical presentation. Available from: https://emedicine.medscape.com/article/1343451-clinical Accessed 2021 Oct 23.
110. Solazzo A, Botta C, Nava F, Baisi A, Bonucchi D, Cappelli G. Interstitial lung disease after kidney transplantation and the role of everolimus. Transplantation Proceedings 2016 Mar;48(2):349-51.
111. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine 2018 Sep;198(5):e44-68.
112. Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis & Rheumatology 2000 Feb;43(2):405-13.
113. Wallis A, Spinks K. The diagnosis and management of interstitial lung diseases. BMJ 2015 May;350:h2072.
114. Министерство здравоохранения РФ; Российское респираторное общество. Методические рекомендации по использованию метода спирометрии, 2016 г. Доступно по: https://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ Ссылка активна на 23.10.2021.
115. Sovijärvi AR, Lemola M, Stenius B, Idänpään-Heikkilä J. Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions. Scandinavian Journal of Respiratory Diseases 1977;58(1):41-50.
116. Johkoh T, Sakai F, Noma S, Akira M, Fujimoto K, Watadani T, Sugiyama Y. Honeycombing on CT; its definition, pathologic correlation, and future direction of its diagnosis. European Journal of Radiology 2014 Jan;83(1):27-31.
117. Romagnoli M, Bigliazzi C, Casoni G, Chilosi M, Carloni A, Dubini A, Gurioli Ch, Tomassetti S, Gurioli C, Poletti V. The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients. Sarcoidosis, Vasculitis and Diffuse Lung Diseases 2008 Sep;25(1):36-45.
118. Akira M, Ishikawa H, Yamamoto S. Drug-induced pneumonitis: thin-section CT findings in 60 patients. Radiology 2002 Sep;224(3):852-60.
119. Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunology Research 2015 Oct;3(10):1185-92.
120. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS. PD-1 Inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clinical Cancer Research 2016 Dec;22(24):6051-60.
121. Johkoh T, Itoh H, Müller NL, Ichikado K, Nakamura H, Ikezoe J, Akira M, Nagareda T. Crazy-paving appearance at thin-section CT: spectrum of disease and pathologic findings. Radiology 1999 Apr;211(1):155-60.
122. Distefano G, Fanzone L, Palermo M, Tiralongo F, Cosentino S, Inì C, Galioto F, Vancheri A, Torrisi SE, Mauro LA, Foti PV, Vancheri C, Palmucci S, Basile A. HRCT patterns of drug-induced interstitial lung diseases: a review. Diagnostics (Basel, Switzerland) 2020 Apr;10(4):244.
123. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. The Lancet. Respiratory Medicine 2018 Feb;6(2):138-53.
124. Pereira CA, Gimenez A, Kuranishi L, Storrer K. Chronic hypersensitivity pneumonitis. Journal of Asthma and Allergy 2016 Sep;9:171-81.
125. Padley SP, Adler B, Hansell DM, Müller NL. High-resolution computed tomography of drug-induced lung disease. Clinical Radiology 1992 Oct;46(4):232-6.
126. Roden AC, Camus P. Iatrogenic pulmonary lesions. Seminars in Diagnostic Pathology 2018 Jul;35(4):260-71.
127. White DA, Rankin JA, Stover DE, Gellene RA, Gupta S. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. The American Review of Respiratory Disease 1989 Jan;139(1):18-21.
128. Fuhrman C, Parrot A, Wislez M, Prigent H, Boussaud V, Bernaudin JF, Mayaud C, Cadranel J. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. American Journal of Respiratory and Critical Care Medicine 2001 Oct;164(7):1186-91.
129. Huang MS, Colby TV, Goellner JR, Martin WJ Jr. Utility of bronchoalveolar lavage in the diagnosis of drug-induced pulmonary toxicity. Acta Cytologica 1989 Jul-Aug;33(4):533-8.
130. Piciucchi S, Romagnoli M, Chilosi M, Bigliazzi C, Dubini A, Beomonte Zobel B, Gavelli G, Carloni A, Poletti V. Prospective evaluation of drug-induced lung toxicity with high-resolution CT and transbronchial biopsy. La Radiologia Medica 2011 Mar;116(2):246-63.
131. Wieder JA, Soloway MS. Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer. The Journal of Urology 1998 Jun;159(6):2099.
132. Сычев Д.А., Остроумова О.Д., Переверзев А.П., Кочетков А.И., Остроумова Т.М., Клепикова М.В., Аляутдинова И.А., Голобородова И.В. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека 2020;6:113-26.
133. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics 1981 Aug;30(2):239-45.
134. Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, Saijo Y, Sakai F, Sugiyama Y, Tatsumi K, Dohi M, Tokuda H, Hashimoto S, Hattori N, Hanaoka M, Fukuda Y; Japanese Respiratory Society Committee for formulation of Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respiratory Investigation 2013 Dec;51(4):260-77.
135. Министерство здравоохранения РФ; Российское респираторное общество. Клинические рекомендации. Интерстициальный легочный фиброз. Пересмотр 2016 г. Доступно по http://spulmo.ru/obrazovatelnye-resursy/ federalnye-klinicheskie-rekomendatsii/ Ссылка активна на 23.10.2021.
136. Rebattu P, Quantin X, Ardiet C, Morere JF, Azarian MR, Schuller-Lebeau MP, Pujol JL. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 2001 Aug-Sep;33(2-3):277-87.
137. Kakugawa T, Yokota S, Ishimatsu Y, Hayashi T, Nakashima S, Hara S, Sakamoto N, Matsuoka Y, Kubota H, Mine M, Mukae H, Nagata K, Kohno S. Serum heat shock protein 47 levels in patients with drug-induced lung disease. Respiratory Research 2013 Nov;14(1):133.
138. Ki KD, Lee JM, Lee SK, Tong SY, Huh CY, Ryu JK, Kim KY. Pulmonary toxicity after a quick course of combinatorial vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy in cervical cancer. Journal of Korean Medical Science 2010 Feb;25(2):240-4.
139. Takatani K, Miyazaki E, Nureki S, Ando M, Ueno T, Okubo T, Takenaka R, Hiroshige S, Kumamoto T. High-resolution computed tomography patterns and immunopathogenetic findings in drug-induced pneumonitis. Respiratory Medicine 2008 Jun;102(6):892-8.
140. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Klüglich M, du Bois RM. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. The New England Journal of Medicine 2011 Sep;365(12):1079-87.
141. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. The New England Journal of Medicine 2014 May;370(22):2071-82.
142. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. The Lancet 2011 May;377(9779):1760-9.
143. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine 2014 May;370(22):2083-92.
144. Chap L, Shpiner R, Levine M, Norton L, Lill M, Glaspy J. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. Bone Marrow Transplantation 1997 Dec;20(12):1063-7.
145. Faress JA, Nethery DE, Kern EF, Eisenberg R, Jacono FJ, Allen CL, Kern JA. Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2. Journal of Applied Physiology (Bethesda, Md.: 1985) 2007 Dec;103(6):2077-83.
146. Günther A, Lübke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, Markart P, Ruppert C, Quanz K, Ermert L, Grimminger F, Seeger W. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. American Journal of Respiratory and Critical Care Medicine 2003 Dec;168(11):1358-65.
147. Punithavathi D, Venkatesan N, Babu M. Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats. British Journal of Pharmacology 2003 Aug;139(7):1342-50.
148. Mata M, Ruíz A, Cerdá M, Martinez-Losa M, Cortijo J, Santangelo F, Serrano-Mollar A, Llombart-Bosch A, Morcillo EJ. Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats. The European Respiratory Journal 2003 Dec;22(6):900-5.
149. Bendstrup E, Hyldgaard C, Agerbæk M, Andersen CU, Hilberg O. No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis. Respiratory Medicine Case Reports 2014 May;12:47-9.
150. Lessnau KD. Drug-induced pulmonary toxicity treatment & management. Available from: https://emedicine.medscape.com/article/1343451-treatment Accessed 2021 Oct 23.
151. Chetta A, Marangio E, Olivieri D. Pulmonary function testing in interstitial lung diseases. Respiration 2004 May-Jun;71(3):209-13.
152. Gleadhill IC, Wise RA, Schonfeld SA, Scott PP, Guarnieri T, Levine JH, Griffith LS, Veltri EP. Serial lung function testing in patients treated with amiodarone: a prospective study. The American Journal of Medicine 1989 Jan;86(1):4-10.
153. Limper AH, Rosenow EC 3rd. Drug-induced interstitial lung disease. Current Opinion in Pulmonary Medicine 1996 Sep;2(5):396-404.
154. McGaughey DS, Nikcevich DA, Long GD, Vredenburgh JJ, Rizzieri D, Smith CA, Broadwater G, Loftis JS, McDonald C, Morris AK, Folz RF, Chao NF. Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Biology of Blood and Marrow Transplantation 2001;7(5):274-8.
155. Tabata C, Tabata R, Kadokawa Y, Hisamori S, Takahashi M, Mishima M, Nakano T, Kubo H. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. Journal of Immunology (Baltimore, Md.: 1950) 2007 Jul;179(1):708-14.

References

1. Macdonald G. Harrison’s internal medicine, 17th edition. Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, Loscalzo J, editors. Internal Medicine Journal 2008 Dec;38(12):932.
2. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine 2013 Sep;188(6):733-48.
3. ICD-10: J80-J84 – other respiratory diseases affecting mainly interstitial tissue. Available from: https://mkb10.su/J80-J84.html Accessed 2021 Oct 23. (In Russian).
4. Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018: 431-49.
5. ICD-10: J70 – respiratory conditions caused by other external agents. Available from: https://mkb10.su/J70.html Accessed 2021 Oct 23. (In Russian).
6. Schwaiblmair M, Behr W, Haeckel T, Märkl B, Foerg W, Berghaus T. Drug-induced interstitial lung disease. The Open Respiratory Medicine Journal 2012;6:63-74.
7. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. American Journal of Respiratory and Critical Care Medicine 1994 Oct;150(4):967-72.
8. Amar RK, Jick SS, Rosenberg D, Maher TM, Meier CR. Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosis. Respirology (Carlton, Vic.) 2012 Jul;17(5):861-8.
9. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of Internal Medicine 2012 May;156(10):684-91.
10. Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. British Journal of Cancer 1998 Oct;78(8):1061-6.
11. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. The European Respiratory Journal 2000 Feb;15(2):373-81.
12. Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone: review of pulmonary effects and toxicity. Drug Safety 2010 Jul;33(7):539-58.
13. Chen YM, Luo YH. Interstitial lung disease induced by targeted therapy for non-small cell lung cancer: a review of diagnosis, workup, and management. Journal of Palliative Care & Medicine 2015;5:204.
14. Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, Giollo A, Wild JM, Waterton JC, Buch M, Linton K, Bruce IN, Leonard C, Bianchi S, Chaudhuri N. Drug-induced interstitial lung disease: a systematic review. Journal of Clinical Medicine 2018 Oct;7(10):356.
15. Collard HR, Ward AJ, Lanes S, Hayflinger DC, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. Journal of Medical Economics 2012;15(5):829-35.
16. Dweik RA. Drug-induced pulmonary disease. In: Textbook of pulmonary diseases. Baum GL, Crapo JD, Celli BR, Karlinsky JB, editors. 2-vol. set. 6th ed. Philadelphia, PA: Lippincott-Raven; 1988: 477-90.
17. Ahmed BM, Al-Zakwani IS. Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman. Journal of Oncology Pharmacy Practice 2013 Mar;19(1):3-7.
18. Tamura M, Saraya T, Fujiwara M, Hiraoka S, Yokoyama T, Yano K, Ishii H, Furuse J, Goya T, Takizawa H, Goto H. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. The Oncologist 2013;18(4):454-9.
19. Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer (Amsterdam, Netherlands) 2014 Feb;83(2):231-9.
20. Osawa M, Kudoh S, Sakai F, Endo M, Hamaguchi T, Ogino Y, Yoneoka M, Sakaguchi M, Nishimoto H, Gemma A. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Journal of Clinical Oncology 2015 Dec;20(6):1063-71.
21. Ishiguro M, Watanabe T, Yamaguchi K, Satoh T, Ito H, Seriu T, Sakata Y, Sugihara K. A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer. Japan Journal of Clinical Oncology 2012 Apr;42(4):287-94.
22. Ou SHI. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Expert Review of Anticancer Therapy 2012 Feb;12(2):151-62.
23. Wu S, Liu K, Ren F, Zheng D, Pan D. Fatal interstitial lung disease associated with crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report. BMC Pulmonary Medicine 2018 Jul;18(1):121.
24. Cooper MR, Chim H, Chan H, Durand C. Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. The Annals of Pharmacotherapy 2015 Jan;49(1):107-12.
25. Bender L, Meyer G, Quoix E, Mennecier B. Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report. Annals of Translational Medicine 2019 Mar;7(5):106.
26. Alkhunaizi AM, Al-Khouzaie TH, Alsagheir AI. Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus. Respiratory Medicine Case Reports 2020 Jun;30:101109.
27. Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 2017 Aug;152(2):271-81.
28. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncology 2016 Dec;2(12):1607-16.
29. Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, Zamami Y, Nishioka Y, Ishizawa K. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Scientific Reports 2020 Aug;10(1):13773.
30. Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 2013 Mar;143(3):858-61.
31. Yoshii N, Suzuki T, Nagashima M, Kon A, Kakihata K, Gemma A. Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports. Anti-cancer Drugs 2011 Jul;22(6):563-8.
32. Otoshi R, Sekine A, Hagiwara E, Okudela K, Katano T, Aiko N, Matama G, Isomoto K, Ikeda S, Baba T, Komatsu S, Ogura T. Pemetrexed-induced interstitial lung disease mimicking hypersensitivity pneumonia: a pathologically proven case. Internal Medicine (Tokio, Japan) 2019 Sep;58(18):2679-82.
33. Iki S, Yoshinaga K, Ohbayashi Y, Urabe A. Cytotoxic drug-induced pneumonia and possible augmentation by G-CSF – clinical attention. Annals of Hematology 1993 Apr;66(4):217-8.
34. Yamasaki K, Yatera K, Noguchi S, Oda K, Akata K, Nishida C, Kawanami T, Kawanami Y, Ishimoto H, Ono S, Wakuta Y, Mukae H. Incidence and outcomes of bepridil-induced interstitial pneumonia. Respiratory Medicine 2013 Dec;107(12):2088-91.
35. Pervaiz S, Homsy S, Narula N, Ngu S, Elsayegh D. Bevacizumab-induced pneumonitis in a patient with metastatic colon cancer: a case report. Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine 2020 Jun;14:1179548420929285.
36. Yamaguchi T, Seki T, Miyasaka C, Inokuchi R, Kawamura R, Sakaguchi Y, Murata M, Matsuzaki K, Nakano Y, Uemura Y, Okazaki K. Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: an autopsy case report. Oncology Letters 2015 Apr;9(4):1633-6.
37. Naqibullah M, Shaker SB, Bach KS, Bendstrup E. Rituximab-induced interstitial lung disease: five case reports. European Clinical Respiratory Journal 2015 May 21;2. doi: 10.3402/ecrj.v2.27178. eCollection 2015.
38. Nishino M, Boswell EN, Hatabu H, Ghobrial IM, Ramaiya NH. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenström macroglobulinemia as a paradigm. Oncologist 2015 Sep;20(9):1077-83.
39. Kharel P, Uprety D, Chandra AB, Hu Y, Belur AA, Dhakal A. Bortezomib-induced pulmonary toxicity: a case report and review of literature. Case Reports in Medicine 2018 Nov;2018:2913124.
40. Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P, Malcovati L, Nascimbene C, Varettoni M, Volpini E, Klersy C, Bernasconi C. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplantation 2000 Feb;25(3):309-13.
41. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis & Rheumatology (Hoboken, N.J.) 2014 Apr;66(4):803-12.
42. Drosos AA, Psychos D, Andonopoulos AP, Stefanaki-Nikou S, Tsianos EB, Moutsopoulos HM. Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up. Clinical Rheumatology 1990 Sep;9(3):333-41.
43. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ 2015 Mar;350:h1269.
44. Sen S, Peltz C, Jordan K, Boes TJ. Infliximab-induced nonspecific interstitial pneumonia. The American Journal of the Medical Sciences 2012 Jul;344(1):75-8.
45. Manfredi A, Cassone G, Furini F, Gremese E, Venerito V, Atzeni F, Arrigoni E, Della Casa G, Cerri S, Govoni M, Petricca L, Iannone F, Salvarani C, Sebastiani M. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Internal Medicine Journal 2020 Sep;50(9):1085-90.
46. Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, Joh T, Ohtsu A. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Annals of Oncology 2010 Oct;21(10):2005-10.
47. Yoneda KY, Cross CE. The pulmonary toxicity of anticancer agents. In: Respiratory Toxicology. Vol. 8. Elsevier; 2010: 477-510.
48. Matijasic N, Bonevski A, Pivac VT, Pavic I. Busulfan-induced lung injury in pediatric oncology patients-review of the literature with an illustrative case. Pediatric Allergy, Immunology, and Pulmonology 2019 Sep;32(3):86-91.
49. Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, Matsuda T, Takemura T, Sagawa A; Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford, England) 2009 Sep;48(9):1069-72.
50. Smith W, Ball GV. Lung injury due to gold treatment. Arthritis & Rheumatology 1980 Mar;23(3):351-4.
51. Fernández AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008 Oct;134(4):824-30.
52. Santos JM, Batech M, Pelter MA, Deamer RL. Evaluation of the risk of nitrofurantoin lung injury and its efficacy in diminished kidney function in older adults in a large integrated healthcare system: a matched cohort study. Journal of the American Geriatrics Society 2016 Apr;64(4):798-805.
53. Higashi Y, Nakamura S, Tsuji Y, Ogami C, Matsumoto K, Kawago K, Tokui K, Hayashi R, Sakamaki I, Yamamoto Y. Daptomycin-induced eosinophilic pneumonia and a review of the published literature. Internal Medicine (Tokio, Japan) 2018 Jan;57(2):253-8.
54. Mankikian J, Favelle O, Guillon A, Guilleminault L, Cormier B, Jonville-Béra AP, Perrotin D, Diot P, Marchand-Adam S. Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. Respiratory Medicine 2014 Apr;108(4):638-46.
55. Vanina B, Delay M, Vigreux P, Montastruc JL, Lapeyre-Mestre M. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. American Journal of Therapeutics 2006 Jul-Aug;13(4):315-9.
56. Tisdale JE, Follin SL, Ordelova A, Webb CR. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. Journal of Clinical Pharmacology 1995 Apr;35(4):351-6.
57. Pollak PT, Sharma AD, Carruthers SG. Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. The American Journal of Cardiology 1990 May;65(18):1185-91.
58. Hanston P, Evrard P, Mahieu P, Wallemacq P, Friob M, Hassoun A. Flecainide-associated interstitial pneumonitis. The Lancet 1991 Feb;337(8737):371-2.
59. Pesenti S, Lauque D, Daste G, Boulay V, Pujazon MC, Carles P. Diffuse infiltrative lung disease associated with flecainide. Report of two cases. Respiration 2002;69(2):182-5.
60. Akoun GM, Cadranel JL, Israel-Biet D, Gauthier-Rahman S. Flecainide-associated pneumonitis. The Lancet 1991 Jan;337(8732):49.
61. Deidda A, Pisanu C, Micheletto L, Bocchetta A, Del Zompo M, Stochino ME. Interstitial lung disease induced by fluoxetine: systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database. Pharmacological Research 2017 Jun;120:294-301.
62. Turner RC, Nelson JE, Roberts BT, Gillam DM. Venlafaxine-associated interstitial pneumonitis. Pharmacotherapy 2005 Apr;25(4):626-9.
63. Thornton C, Maher TM, Hansell D, Nicholson AG, Wells AU. Pulmonary fibrosis associated with psychotropic drug therapy: a case report. Journal of Medical Case Reports 2009 Nov;3:126.
64. Espeleta VJ, Moore WH, Kane PB, Baram D. Eosinophilic pneumonia due to duloxetine. Chest 2007 Mar;131(3):901-3.
65. Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleveland Clinic Journal of Medicine 2001 Sep;68(9):782-5, 789-95.
66. Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Digestive Diseases and Sciences 2010 Mar;55(3):579-85.
67. Camus P. The Drug-Induced Respiratory Disease Website. Available from: https://www.pneumotox.com/drug/index/ Accessed 2021 Oct 23.
68. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Seminars in Arthritis and Rheumatism 2014 Apr;43(5):613-26.
69. O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Annals of Oncology 2003 Jan;14(1):91-6.
70. Schmitz N, Diehl V. Carmustine and the lungs. The Lancet 1997 Jun;349(9067):1712-3.
71. Min JH, Lee HY, Lim H, Ahn MJ, Park K, Chung MP, Lee KS. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemotherapy and Pharmacology 2011 Nov;68(5):1099-109.
72. Roelandt M, Demedts M, Callebaut W, Coolen D, Slabbynck H, Bockaert J, Kips J, Brie J, Ulburghs M, De Boeck K. Epidemiology of interstitial lung disease (ILD) in flanders: registration by pneumologists in 1992–1994. Working group on ILD, VRGT. Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding. Acta Clinica Belgica 1995;50(5):260-8.
73. Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology 1994 Jul;107(1):266-70.
74. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Canadian Respiratory Journal 2009 Mar-Apr;16(2):43-8.
75. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respiratory Research 2012;13(1):39.
76. Ryrfeldt A. Drug-induced inflammatory responses to the lung. Toxicology Letters 2000 Mar;112-3:171-6.
77. Mendez JL, Nadrous HF, Hartman TE, Ryu JH. Chronic nitrofurantoin-induced lung disease. Mayo Clinic Proceedings 2005 Oct;80(10):1298-302.
78. Kim YJ, Song M, Ryu JC. Mechanisms underlying methotrexate-induced pulmonary toxicity. Expert Opinion on Drug Safety 2009 Jul;8(4):451-8.
79. Lee WI, Hissaria P. Drug-induced interstitial lung disease. Indian Journal of Rheumatology 2019;14(5):19-26.
80. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer (Amsterdam, Netherlands) 2004 Jul;45(1):93-104.
81. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Research 2003 Aug;63(16):5054-9.
82. Baritussio A, Marzini S, Agostini M, Alberti A, Cimenti C, Bruttomesso D, Manzato E, Quaglino D, Pettenazzo A. Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes. American Journal of Physiology. Lung Cellular and Molecular Physiology 2001 Nov;281(5):L1189-99.
83. Cooper JA Jr, Zitnik RJ, Matthay RA. Mechanisms of drug-induced pulmonary disease. Annual Review of Medicine 1988;39:395-404.
84. Coombs PRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Clinical aspects of immunology. Gell PRA, editor. Oxford: Oxford University Press; 1968: 575-96.
85. Schnyder B, Pichler WJ. Mechanisms of drug-induced allergy. Mayo Clinic Proceedings 2009 Mar;84(3):268-72.
86. Gruchalla RS. Drug metabolism, danger signals, and drug-induced hypersensitivity. The Journal of Allergy and Clinical Immunology 2001 Oct;108(4):475-88.
87. Matzinger P. The danger model: a renewed sense of self. Science 2002 Apr;296(5566):301-5.
88. Partanen J, van Assendelft AH, Koskimies S, Forsberg S, Hakala M, Ilonen J. Patients with rheumatoid arthritis and gold-induced pneumonitis express two high-risk major histocompatibility complex patterns. Chest 1987 Aug;92(2):277-81.
89. Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms AM, van de Putte LB. Methotrexate-related pulmonary complications in rheumatoid arthritis. Annals of the Rheumatic Diseases 1994 Jul;53(7):434-9.
90. White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. American Journal of Respiratory and Critical Care Medicine 2010 Aug;182(3):396-403.
91. Camus P, Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Clinics in Chest Medicine 2004 Mar;25(1):65-75.
92. Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clinics in Chest Medicine 1990 Mar;11(1):1-20.
93. Aronin PA, Mahaley MS Jr, Rudnick SA, Dudka L, Donohue JF, Selker RG, Moore P. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. The New England Journal of Medicine 1980 Jul;303(4):183-8.
94. Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 1997 Mar;111(3):657-60.
95. O’Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. The New England Journal of Medicine 1990 Aug;323(6):378-82.
96. Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, St Clair EW, Sundy JS, Alexander RW, Smith GJ, Axiotis CA. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Annals of Internal Medicine 1997 Sep;127(5):356-64.
97. Tomii K, Kato T, Takahashi M, Noma S, Kobashi Y, Enatsu S, Okubo S, Kobayashi N, Kudoh S. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer). Japanese Journal of Clinical Oncology 2017 Apr;47(4):350-6.
98. Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Minakuchi K, Ishizawa K. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. The Annals of Pharmacotherapy 2015 Apr;49(4):398-404.
99. Camus P, Bonniaud P, Fanton A, Camus C, Baudaun N, Foucher P. Drug-induced and iatrogenic infiltrative lung disease. Clinics in Chest Medicine 2004 Sep;25(3):479-519, vi.
100. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, Narimatsu H, Fujii T, Kawabata M, Taniguchi S, Ozawa K, Oshimi K. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006 May;107(9):3492-4.
101. Ohri A, Arena FP. Severe pulmonary complications in African-American patient after bortezomib therapy. American Journal of Therapeutics 2006 Nov-Dec;13(6):553-5.
102. Iqbal K, Kelly C. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Therapeutic Advances in Musculoskeletal Disease 2015 Dec;7(6):247-67.
103. Wijnen PA, Drent M, Nelemans PJ, Kuijpers PM, Koek GH, Neef C, Haenen GR, Bekers O. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands. Drug Safety 2008;31(12):1125-34.
104. Hamada T, Yasunaga H, Nakai Y, Isayama H, Matsui H, Fushimi K, Koike K. Interstitial lung disease associated with gemcitabine: a Japanese retrospective cohort study. Respirology (Carlton, Vic.) 2016 Feb;21(2):338-43.
105. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004 Jul-Aug;71(4):301-26.
106. Sahin IH, Geyer AI, Kelly DW, O’Reilly EM. Gemcitabine-related pneumonitis in pancreas adenocarcinoma – an infrequent event: elucidation of risk factors and management implications. Clinical Colorectal Cancer 2016 Mar;15(1):24-31.
107. Weiner SM, Sellin L, Vonend O, Schenker P, Buchner NJ, Flecken M, Viebahn R, Rump LC. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome – a single-centre experience and review of the literature. Nephrology, Dialysis, Transplantation 2007 Dec;22(12):3631-7.
108. Daba MH, El-Tahir KE, Al-Arifi MN, Gubara OA. Drug-induced pulmonary fibrosis. Saudi Medical Journal 2004 Jun;25(6):700-6.
109. Lessnau KD. Drug-induced pulmonary toxicity clinical presentation. Available from: https://emedicine.medscape.com/article/1343451-clinical Accessed 2021 Oct 23.
110. Solazzo A, Botta C, Nava F, Baisi A, Bonucchi D, Cappelli G. Interstitial lung disease after kidney transplantation and the role of everolimus. Transplantation Proceedings 2016 Mar;48(2):349-51.
111. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine 2018 Sep;198(5):e44-68.
112. Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis & Rheumatology 2000 Feb;43(2):405-13.
113. Wallis A, Spinks K. The diagnosis and management of interstitial lung diseases. BMJ 2015 May;350:h2072.
114. Ministry of Health of the Russian Federation; Russian Respiratory Society. Methodological recommendations on the use of spirometry method, 2016. Available from: https://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ Accessed 2021 Oct 23. (In Russian).
115. Sovijärvi AR, Lemola M, Stenius B, Idänpään-Heikkilä J. Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions. Scandinavian Journal of Respiratory Diseases 1977;58(1):41-50.
116. Johkoh T, Sakai F, Noma S, Akira M, Fujimoto K, Watadani T, Sugiyama Y. Honeycombing on CT; its definition, pathologic correlation, and future direction of its diagnosis. European Journal of Radiology 2014 Jan;83(1):27-31.
117. Romagnoli M, Bigliazzi C, Casoni G, Chilosi M, Carloni A, Dubini A, Gurioli Ch, Tomassetti S, Gurioli C, Poletti V. The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients. Sarcoidosis, Vasculitis and Diffuse Lung Diseases 2008 Sep;25(1):36-45.
118. Akira M, Ishikawa H, Yamamoto S. Drug-induced pneumonitis: thin-section CT findings in 60 patients. Radiology 2002 Sep;224(3):852-60.
119. Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunology Research 2015 Oct;3(10):1185-92.
120. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS. PD-1 Inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clinical Cancer Research 2016 Dec;22(24):6051-60.
121. Johkoh T, Itoh H, Müller NL, Ichikado K, Nakamura H, Ikezoe J, Akira M, Nagareda T. Crazy-paving appearance at thin-section CT: spectrum of disease and pathologic findings. Radiology 1999 Apr;211(1):155-60.
122. Distefano G, Fanzone L, Palermo M, Tiralongo F, Cosentino S, Inì C, Galioto F, Vancheri A, Torrisi SE, Mauro LA, Foti PV, Vancheri C, Palmucci S, Basile A. HRCT patterns of drug-induced interstitial lung diseases: a review. Diagnostics (Basel, Switzerland) 2020 Apr;10(4):244.
123. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. The Lancet. Respiratory Medicine 2018 Feb;6(2):138-53.
124. Pereira CA, Gimenez A, Kuranishi L, Storrer K. Chronic hypersensitivity pneumonitis. Journal of Asthma and Allergy 2016 Sep;9:171-81.
125. Padley SP, Adler B, Hansell DM, Müller NL. High-resolution computed tomography of drug-induced lung disease. Clinical Radiology 1992 Oct;46(4):232-6.
126. Roden AC, Camus P. Iatrogenic pulmonary lesions. Seminars in Diagnostic Pathology 2018 Jul;35(4):260-71.
127. White DA, Rankin JA, Stover DE, Gellene RA, Gupta S. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. The American Review of Respiratory Disease 1989 Jan;139(1):18-21.
128. Fuhrman C, Parrot A, Wislez M, Prigent H, Boussaud V, Bernaudin JF, Mayaud C, Cadranel J. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. American Journal of Respiratory and Cri

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]